Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

AstraZeneca AZ

AstraZeneca launches diabetes lifestyle campaign

Aims to support people with type 2 diabetes in becoming more active

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

AstraZeneca AZ

AZ’s Brilinta disappoints in stroke trial

Antiplatelet drug fails to demonstrate significant benefit in ischaemic stroke

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

EU flag

EMA initiative aims to fast-track important new drugs

Hopes PRIME programme will foster greater cooperation with industry 

AstraZeneca AZ global R&D corporate HQ

AZ’s influenza drug fast tracked in US

FDA expedites MEDI8852 to help meet an acute need for new flu treatments

AstraZeneca AZ global R&D corporate HQ

AZ offloads more products in slimming drive

Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline

AstraZeneca AZ global R&D corporate HQ

AZ’s tremelimumab fails mesothelioma trial

FDA-designated breakthrough therapy did not demonstrate increase in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links